P4388Treatment decisions based on individual estimated lifetime benefit versus individual estimated 10-year absolute risk reduction: a cost-effectiveness analyses with PCSK9 inhibition. (28th August 2018) - Berkelmans, G F N; Greving, J P; Van Der Graaf, Y; Visseren, F L J; Dorresteijn, J A N